Brexpiprazole (Rexulti®) for “agitation associated with dementia due to Alzheimer’s disease”

In May 2023, the FDA approved an additional indication for brexpiprazole (Rexulti®). The wording of the indication states: “Treatment of agitation associated with dementia due to Alzheimer’s disease”. The special significance of this FDA approval was that this was the first time that ANY treatment was approved by the FDA for this indication. Note: In…